drugset / Trial / NCT04045730
The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label single arm phase 2 study for patients with metastatic pancreatic ductal adenocarcinoma who have not received any prior systemic therapies.
Timeline
- Start
- 2019-11-15
- Primary completion
- 2019-12-31
- Completion
- 2021-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pegvorhyaluronidase Alfa | Protein / enzyme biologic | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |